DelveInsight’s “Chronic Pancreatitis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Chronic Pancreatitis pipeline landscapes. It comprises Chronic Pancreatitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chronic Pancreatitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chronic Pancreatitis pipeline products.
Some of the key takeaways of the Chronic Pancreatitis Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Kangen Pharmaceutical, AzurRx BioPharma, Therapy Fibrosisetc., are developing therapies for the treatment of Chronic Pancreatitis.
-
Emerging therapies such as NI-03, MS1819-SD, TLY012, are expected to have a significant impact on the Chronic Pancreatitis market in the coming years.
-
The market Size of chronic pancreatitis (CP) in the 7MM is estimated to reach 2,119 million by 2030.
-
The market size shall increase during the forecast period (2020–2030), owing to the launch of upcoming therapies.
Get an overview of pipeline landscape @ Chronic Pancreatitis Clinical Trials Analysis
Chronic pancreatitis is a long-standing inflammation of the pancreas that alters the organ’s normal structure and functions. It can present as episodes of acute inflammation in a previously injured pancreas, or as chronic damage with persistent pain or malabsorption.
Chronic Pancreatitis Emerging Drugs
-
NI-03 by Kangen Pharmaceutical
-
MS1819-SD by AzurRx BioPharma
-
TLY012 by Theraly Fibrosis
For further information, refer to the detailed report @ Chronic Pancreatitis Pipeline Therapeutics
Scope of Chronic Pancreatitis Pipeline Drug Insight
-
Coverage: Global
-
Major Players:Kangen Pharmaceutical,AzurRx BioPharma,Theraly Fibrosis and others.
-
Pipeline Therapies: NI-03, MS1819-SD, TLY012, and others.
Table of Contents
|
1 |
Chronic Pancreatitis Report Introduction |
|
2 |
Chronic Pancreatitis Executive Summary |
|
3 |
Chronic Pancreatitis Overview |
|
4 |
Chronic Pancreatitis- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Chronic Pancreatitis Pipeline Therapeutics |
|
6 |
Chronic Pancreatitis Late Stage Products (Phase II/III) |
|
7 |
Chronic Pancreatitis Mid Stage Products (Phase II) |
|
8 |
Chronic Pancreatitis Early Stage Products (Phase I) |
|
9 |
Chronic Pancreatitis Preclinical Stage Products |
|
10 |
Chronic Pancreatitis Therapeutic Assessment |
|
11 |
Chronic Pancreatitis Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Chronic Pancreatitis Key Companies |
|
14 |
Chronic Pancreatitis Key Products |
|
15 |
Chronic Pancreatitis Unmet Needs |
|
16 |
Chronic Pancreatitis Market Drivers and Barriers |
|
17 |
Chronic Pancreatitis Future Perspectives and Conclusion |
|
18 |
Chronic Pancreatitis Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/